Literature DB >> 16802521

[Chronic inflammatory bowel disease and cardiovascular complications].

Philipp Rellecke1, Bodo Eckehard Strauer.   

Abstract

The most common extraintestinal manifestations of Crohn's disease and ulcerative colitis are iritis and uveitis, primary sclerosing cholangitis (PSC) and nodal erythema and pyoderma gangrenosum. Complications within the cardiovascular system seem to be uncommon, but there are no systematic investigations concerning the epidemiology of these manifestations. There are more than 100 cases reported about pericarditis and perimyocarditis in patients with inflammatory bowel disease. Other patients with Crohn's disease or ulcerative colitis suffer from vasculitis, representing a further mechanism of inflammatory diseases of the cardiovascular system. There are several case reports showing a combination of Takayasu's arteritis and Crohn's disease, and cross-reacting antibodies against gut mucosa and aortic tissue were found. Some patients developed thrombotic complications by activating the coagulation system, which can result in atrial thrombi, embolism of the pulmonary arteries, myocardial infarction and disseminated intravascular coagulopathy (DIC). Furthermore, a few case were reported about atrio ventricular blocks, amyloidosis of the heart, dilative cardiomyopathy and endomyocardial fibrosis in patients with chronic inflammatory bowel disease. Here, a 27-year-old patient with known ulcerative colitis for 2 years is reported, who presented in the authors' department with unstable angina pectoris. Coronary angiographic examination was immediately performed and diffuse intracoronary thrombi were found, which could be removed by the catheter procedure. A myocardial infarction did not develop. Because of positive anti neutrophil cytoplasmic antibodies (p-ANCA) a p-ANCA-positive arteritis of the coronary vessels with intracoronary thromboembolism due to ulcerative colitis was diagnosed. Systematic studies or investigations concerning the epidemiology of the cardiovascular complications are still lacking, so that an overview about the published data is given.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16802521

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  7 in total

1.  Prolonged QT dispersion in inflammatory bowel disease.

Authors:  Elif Yorulmaz; Aslıhan Sezgin; Hatice Yorulmaz; Gupse Adali; Hilmi Ciftci
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

2.  Evaluation of cardiac function by two-dimensional speckle tracking echocardiography in ulcerative colitis patients.

Authors:  Altug Cincin; Murat Sunbul; Tarık Kivrak; Halil Atas; Ibrahim Sari; Kursat Tigen; Tarik Kani; Hakan Akin; Nese Imeryuz; Yelda Basaran
Journal:  Dig Dis Sci       Date:  2014-07-15       Impact factor: 3.199

3.  A study on QT interval in patients affected with inflammatory bowel disease without cardiac involvement.

Authors:  Mario Curione; Annalisa Aratari; Silvia Amato; Marco Colotto; Maria Barbato; Silvia Leone; Andi Tego; Diego Panetti; Claudio Parlapiano
Journal:  Intern Emerg Med       Date:  2010-04-22       Impact factor: 3.397

4.  Takayasu's arteritis associated with Crohn's disease.

Authors:  You-shi Liu; You-hong Fang; Ling-xiang Ruan; You-ming Li; Lin Li; Ling-ling Jiang
Journal:  J Zhejiang Univ Sci B       Date:  2009-08       Impact factor: 3.066

5.  Prolonged P-Wave and QT Dispersion in Children with Inflammatory Bowel Disease in Remission.

Authors:  Helen Aghdasi Bornaun; Nuh Yılmaz; Günsel Kutluk; Reyhan Dedeoğlu; Kazım Öztarhan; Gonca Keskindemirci; Aras Tulunoğlu; Fatih Şap
Journal:  Biomed Res Int       Date:  2017-02-21       Impact factor: 3.411

6.  Mesalazine-induced myocarditis: a case report.

Authors:  Shiva T Radhakrishnan; Aruchuna Mohanaruban; Sami Hoque
Journal:  J Med Case Rep       Date:  2018-02-22

7.  Acute myocardial infarction complicating active ulcerative colitis: a case report.

Authors:  Eva D Papadimitraki; Mubarak Ahamed; Nicholas H Bunce
Journal:  Case Rep Cardiol       Date:  2011-08-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.